3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics (ARCT) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Arcturus Therapeutics Holdings Inc

3rd Annual Guggenheim Healthcare Innovation Conference summary

9 Nov, 2026

2027 catalysts and plans

  • Two mRNA programs have data catalysts in 2027: CF full phase II cohort 4 data in Q2; ARCT-2601 OTC deficiency top-line data in H2.

  • CF cohort 4 enrollment is continuing through year-end 2026; full data are targeted for Q2 2027, with top-line data expected in between and shared alongside the phase III decision.

  • If the CF program advances to phase III, Thermo Fisher is expected to contribute up to $40 million; preparation for the trial began in July 2026.

  • ARCT-2601 clinical trial startup is anticipated in early 2027; initial data from the reformulated candidate are expected in H2 2027.

LUNAR platform and pipeline

  • LUNAR is the lipid nanoparticle delivery technology; LUNAR 1.0 has established safety, tolerability and efficacy in an approved COVID vaccine across 30+ countries and in an OTC deficiency program.

  • LUNAR 2.0 showed 38 times better performance than LUNAR 1.0 in primates; the formulation is being applied to OTC deficiency with a focus on less frequent dosing and greater convenience.

  • The reformulated OTC candidate may enable monthly, lower-dose administration at home instead of clinic dosing every two weeks; this is a proposed goal, subject to clinical results.

  • PKU has been added to the pipeline, with an IND targeted for H2 2027; LUNAR 2.0 is presented as enabling liver targets that previously required impractical dosing frequency.

Cystic fibrosis program

  • The inhaled mRNA therapy aims to produce new CFTR protein in lung cells, addressing Class I patients who lack a transporter; about 15% of the CF population do not benefit from modulators, with roughly half of that group Class I.

  • Earlier dose-ranging tested 5, 10 and 15 mg once daily for about four weeks; CT scans at 10 mg showed improvements in mucus plugging and airway obstruction.

  • The ongoing 12-week study uses 10 mg once daily, enrolling up to 20 patients in the U.S., Turkey and Israel; measures include spirometry, lung clearance index, quality-of-life assessments and high-resolution CT.

  • Eligibility was narrowed to 45%–85% predicted lung function, and screening-to-baseline reproducibility criteria were tightened to reduce measurement variability.

  • Phase III go/no-go will consider the totality of lung-function, imaging and quality-of-life data; stability or improvement versus expected decline would be viewed positively.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Arcturus Therapeutics